2OKA M, NODA Y, OCHI Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties[J]. J Pharmacol Exp Ther, 1993, 264(1): 158-165.
3EMMA D, GILLIAN M. Blonanserin: A review of its use in the management of schizophrenia[J]. CNS Drugs, 2010, 24 ( 1 ) : 65- 84.
4MIURA S. Clinical evaluation of blonanserin for schizophrenia : a randomized study comparing blonanserin with risperidone[English abstract] [J]. Jpn J Clin Psychopharmacol, 2008, (11) : 297- 314.
5HADDAD PM, SHARMA SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications[J]. CNS Drugs, 2007, 21 (11): 911-936.
6RICHELSON E. Receptor pharmacology of neuroleptics: relation to clinical effects[J]. J Clin Psychiatry, 1999, 60 Suppl 10: 5- 14.
7OKA M, NODA Y, OCHI Y, et ol. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties[J]. J Pharmacol Exp Ther, 1993, 264 (1): 158-165.
8NODA Y, KURUMIYA S, MIURA Y, et al. Comparative study of 2- (4-ethyl-l-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta [b]pyridine (AD-5423)and haloperidol for their pharmacological activities related to antipsyehotic efficacy and/or adverse side-effects[J]. J Pharmacol Exp Ther, 1993, 265 (2) : 745 -751.
9NAGAI T, NODA Y, UNE T, et al. Effect of AD-5423 on animal models of schizophrenia: phencyelidine-induced behavioural changes in mice[J]. Neuroreport, 2003, 14 (2) : 269-272.
10YOKOTA K, TATEBAYASHI H, MATSUO T, et ol. The effects of neuroleptics on the GABA-induced Cl^- current in rat dorsal root ganglion neurons: differences be tween some neuroleptics[J]. Br J Pharmacol, 2002, 135 (6): 1547-1555.
